A probe into the work of a researcher who studied natural products for cancer had many stops and starts along the way — including five extensions granted by the U.S. Office of Research Integrity — according to documents obtained by Retraction Watch.
Six months ago, the media was ablaze with the findings of a new paper, showing that nearly six percent of cancer cases are caused, at least in part, by obesity and diabetes. But this week, the journal retracted that paper — and replaced it with a revised version.
The new paper doesn’t change the main findings much — the share of all cancers attributable to diabetes and obesity changed from 5.6% to 5.7%, which wouldn’t change any headlines about the original paper. But soon after the paper was published, a group of researchers noticed the authors’ mistake — which was significant enough to prompt the journal to retract the paper entirely, and swap it with a new one.
The former researcher at the University of Texas MD Anderson Cancer Center swapped her own blood samples for those taken from 98 human subjects. The misconduct affects two grant progress reports and two papers; one paper has already been retracted, and the former “research interviewer” — Maria Cristina Miron Elqutub — has agreed to correct or retract the other.
Adel El-Naggar, a co-author on both of the papers also based at the University of Texas MD Anderson Cancer Center, told Retraction Watch:
How much role did a potentially problematic paper play in the demise of a once-promising compound?
Researchers are questioning the validity of a high-profile article, published by Nature in 2006. Although the letter is 12 years old, the concerns have current implications: It was among the early evidence used to develop a cancer compound that recently failed a number of clinical trials.
It’s unclear whether the problems with the paper — if validated — could have contributed to the compound’s demise. But an outside expert has some thoughts — and so do image experts and multiple external reports, including one released this month, which agree the concerns about the figures have merit. (The first author’s ex-husband isn’t too happy with the article, either.)
PNAS has corrected a highly cited paper after an investigation found evidence of misconduct.
The investigation—conducted jointly by the University of California, San Francisco, and the San Francisco Veterans Administration Medical Center—uncovered image manipulation in Figure 2D, which “could only have occurred intentionally.” The institutions, however, could not definitively attribute the research misconduct to any individual.
According to the notice, the UCSF-VA committee determined that a correction to the 2008 PNAS paper—which explores the genetic underpinnings of prostate cancer—was “appropriate,” and the authors have now replaced the problematic figure with a corrected version. The 2008 paper has been cited 630 times, according to Clarivate Analytics’ Web of Science.
A cancer researcher based at The Ohio State University has retracted five papers from one journal, citing concerns about figures.
The notices for all five papers state the Journal of Biological Chemistry raised questions about some figures, and the authors were not able to supply raw data in all instances. Four of the notices say the authors offered to submit data from repeat experiments and corrected figures, which the journal declined.
According to Kaoru Sakabe, data integrity manager at JBC, the authors “agreed to withdraw these articles after we declined their offers.”